Skip to main content
ST PHARM CO., LTD. logo

ST PHARM CO., LTD. — Investor Relations & Filings

Ticker · 237690 ISIN · KR7237690003 KO Manufacturing
Open in API
Filings indexed 399 across all filing types
Latest filing 2024-02-01 Earnings Release
Country KR South Korea
Listing KO 237690

About ST PHARM CO., LTD.

https://www.stpharm.co.kr/en

ST PHARM CO., LTD. is a global Contract Development and Manufacturing Organization (CDMO) specializing in Active Pharmaceutical Ingredients (APIs). The company provides technology-driven manufacturing services for gene therapies, with core expertise in oligonucleotides and various forms of RNA (xRNA), including messenger RNA (mRNA). In addition to nucleic acid-based medicines, ST Pharm offers custom manufacturing for small molecule APIs. The company's services operate under cGMP (current Good Manufacturing Practice) standards, providing comprehensive solutions that support the entire drug development lifecycle, from research and development to commercial-scale production for its global pharmaceutical partners.

Recent filings

Filing Released Lang Actions
연결재무제표기준영업(잠정)실적(공정공시)
Earnings Release Classification · 100% confidence The document is a 'Preliminary Earnings Report' (영업(잠정)실적) for ST Pharm. It provides a summary table of key financial metrics (revenue, operating profit, net income) for the 4th quarter of 2023 compared to previous periods. This is a standard initial announcement of financial results, which fits the definition of an Earnings Release (ER). It is not a full annual report (10-K) or a transcript (CT), and it is not merely an announcement of a report (RPA) as it contains the actual financial data figures. Q4 2023
2024-02-01 Korean
[기재정정]단일판매ㆍ공급계약체결
Regulatory Filings Classification · 100% confidence The document is a regulatory filing from the Korea Exchange (KRX) system regarding a 'Correction Report' (정정신고) for a 'Single Sale/Supply Contract' (단일판매ㆍ공급계약체결). It details changes to a previously disclosed contract, specifically extending the contract end date and updating disclosure status. Since this is a specific regulatory disclosure regarding a material contract update and does not fit into categories like financial reports or shareholder meetings, it is classified as a Regulatory Filing (RNS).
2024-01-31 Korean
기업설명회(IR)개최
Report Publication Announcement Classification · 100% confidence The document is a short announcement regarding the scheduling and logistics of an upcoming Investor Relations (IR) conference call. It provides the date, time, location, and purpose of the event (discussing 2023 Q4 and annual results). Since it is an announcement of an event rather than the actual presentation slides or the full transcript, and it is under 5,000 characters, it falls under the category of a Report Publication Announcement or general regulatory filing regarding corporate events.
2024-01-30 Korean
결산실적공시예고
Report Publication Announcement Classification · 100% confidence The document is a short notice titled '결산실적공시 예고' (Notice of Earnings Disclosure) from ST Pharm. It informs shareholders of the upcoming date for the release of their annual financial results. Since it is a brief announcement regarding the timing of a future report publication rather than the financial report itself, it falls under the Report Publication Announcement category.
2024-01-29 Korean
주식등의대량보유상황보고서(약식)
Major Shareholding Notification Classification · 100% confidence The document is a 'Report on the Status of Large Shareholdings' (주식등의 대량보유상황보고서) filed by the National Pension Service regarding their stake in ST Pharm Co., Ltd. This is a standard regulatory filing in South Korea (often referred to as a 5% rule filing) used to notify the market when a major shareholder's stake crosses a reporting threshold. It does not fit into the categories of annual reports, earnings releases, or management reports, and is specifically a disclosure of share ownership changes. Therefore, it is classified as a Major Shareholding Notification.
2024-01-08 Korean
[기재정정]단일판매ㆍ공급계약체결
Regulatory Filings Classification · 100% confidence The document is a regulatory filing from a Korean company (ST Pharm) regarding a 'Correction Report' (정정신고) for a previously disclosed 'Single Sales/Supply Contract' (단일판매ㆍ공급계약체결). It details the amendment of a contract disclosure, specifically regarding the confidentiality of the counterparty. Since this is a specific regulatory disclosure regarding a material contract update filed with the exchange, it falls under the 'Regulatory Filings' category as it does not fit into the more specific categories like M&A or Share Issues.
2023-12-22 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.